New US tests must detect subtype-O
This article was originally published in Clinica
Executive Summary
The US FDA says any new kits submitted for approval will now be expected to detect subtype-O reliably, following the first CDC report of a case in the US. The infection was detected in a woman who had repeatedly tested negative for HIV-1 but who had symptoms of AIDS. It was identified after PCR with group-O primers. The patient, who has lived in the US since 1994, is believed to have acquired the infection in West Central Africa - like all but one or two of the handful of cases detected in Europe.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.